WASHINGTON, Aug. 20, 2024 (Korea Bizwire) – Virologist and vaccine development leader Kelly Warfield has joined the Sabin Vaccine Institute as its Research & Development President to drive Sabin’s current candidate vaccines toward licensure and expand its pipeline. A member of Sabin’s executive team, Warfield will manage the R&D program and team, collaborating with peers, [...]
The GVN MPOX Action Committee is poised to mobilize resources and catalyze efforts in the urgent global call to action TAMPA, Fla., Aug. 16, 2024 (Korea Bizwire) – As the World Health Organization (WHO) declares MPOX a public health emergency of international concern, the Global Virus Network (GVN), headquartered at the University of South Florida (USF), [...]
Protocol SmartDesign and Investigator SmartSelect bring treatments to patients faster by accelerating clinical trial development NEW YORK, Aug. 13, 2024 (Korea Bizwire) – Citeline, a leader in intelligence solutions for the life sciences industry, has launched two new products — Protocol SmartDesign and Investigator SmartSelect — in its Citeline SmartSolutions suite accelerating the path from pipeline [...]
August 13, 2024 Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Isala hospital (Zwolle, The Netherlands) have renewed their long-term strategic partnership to enhance healthcare delivery through innovative and cost-effective solutions. This collaboration aims to ensure healthcare remains accessible, available, and affordable by leveraging Philips’ advanced technology, data analytics, [...]
SHANGHAI, Aug. 12, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (NMPA) has accepted for review the supplemental new drug application (sNDA) for toripalimab (trade name: [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalmology portfolio and increases access for patients Expected to be key biosimilar growth driver in US Basel, August 12, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, [...]
Operational complementarities expected to yield annual synergies of approximately $100 million Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform Combined business positioned to leverage latest advances in the life sciences and technology to deliver [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD) Half-year net sales of USD 5.0 billion, up 7% in constant currencies [...]
Ad hoc announcement pursuant to Art. 53 LR Baar, Switzerland, August 6, 2024 First half-year 2024 at a glance: Net revenue of CHF 142.1 million (H1/2023: CHF 150.2 million), reflecting a decrease of 2.7% at constant currencies (-5.4% at actual currencies). While the key markets (such as DACH region, Nordics and the Netherlands) performed in line [...]
August 5, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase shares for an amount of up to EUR 125 million to cover certain of its obligations arising from its long-term incentive plans. At the current share price, this represents a total of approximately 4.8 million shares. The repurchases [...]